Liothyronine is a TIGIT/PVR Blocker for Cancer and Immunity Research
Cancer immunotherapy, particularly PD-1/PD-L1 blockade, has seen remarkable success. However, patients can develop adaptive resistance to this treatment. To improve efficacy, combination strategies like pairing PD-1/PD-L1 blockade with radiotherapy or…